I have been a registered nurse for more than thirty years. I am also a bariatric surgery patient and a glucagon-like peptide-1 (GLP-1) user.
I thought that combination would put me in a good position when I started treatment. I understood medications and adverse effects. I knew hydration, nutrition, and maintaining strength mattered, and that success could not be measured only by the scale. Even so, I found myself working things out as I went along.
That bothered me, because I kept thinking about the person starting the same medication without a clinical background. If I was having to stop and think carefully about what my body needed, what was happening to people who had never been taught any of this?
The prescription told me what medication I was taking and how to take it. It did not tell me what it would actually be like to live with the changes the medication produced.
GLP-1 medications are becoming part of everyday health care. In a KFF poll published in November 2025, 12 percent of U.S. adults (about one in eight) said they were currently taking a GLP-1 medication for weight loss, diabetes, or another chronic condition.
Much of the public conversation still concentrates on whether these medications work. For many people, they clearly do. I think we also need to ask what support someone needs while taking them.
When my own appetite changed, I learned that there is a considerable difference between knowing clinically that reduced appetite is an expected effect and actually living with very little interest in food. For someone who has spent years struggling with hunger or persistent thoughts about food, that change can feel extraordinary. It can feel like relief.
But the body still needs nourishment even when the desire to eat has become quiet. There were times when I had to be much more deliberate about whether I had eaten enough, drunk enough, or taken in enough protein. I had to pay attention to constipation and other side effects rather than simply accepting them as the price of treatment. I also began thinking differently about hunger itself.
If someone has spent years believing that hunger is the enemy, what happens when it largely disappears? What happens emotionally if it later returns? Does normal hunger begin to feel like evidence that the treatment, or the person, has failed? Those are not questions every patient will struggle with, but they are worth discussing before someone encounters them alone.
Research is beginning to show how complex this area is. A 2026 systematic review and meta-analysis of 25 randomized controlled trials involving 8,069 participants found reductions in binge-eating-related behaviors, loss-of-control eating, and emotional eating among people receiving GLP-1 receptor agonists. The findings are interesting but should not be overstated. Most included trials had a high risk of bias, and few specifically recruited people with a clinical diagnosis of binge-eating disorder.
We also know that stopping treatment can be difficult. In the STEP 1 trial extension, participants who stopped semaglutide regained, on average, about two-thirds of the weight they had previously lost during the following year. I do not see that as evidence that the medication failed. It is evidence that obesity is a chronic condition and that patients need realistic conversations about what continuing, changing, or stopping treatment may mean.
Body composition deserves the same care. Some clinical trials of GLP-1-based therapies have reported reductions in lean mass during weight loss, although the amount varies considerably between studies. That is another reason to look beyond the scale and talk about nutrition, physical function, and maintaining strength.
None of this means prescribers are failing their patients. In many settings, clinicians are already trying to cover dosage, titration, adverse effects, comorbidities, medication interactions, monitoring, cost, and follow-up in a short consultation.
ADVERTISEMENT
Then the patient goes home and has to live the other 167 hours of that week.
That is the part of GLP-1 care I think we have underestimated. A patient can be losing weight successfully and still be wondering whether they are eating enough. They may not know whether persistent nausea should be reported or simply tolerated. They may feel weaker. Constipation may go on longer than it should. A plateau can feel like proof that the medication has stopped working. Hunger returning can be frightening when nobody has explained that appetite can change over time.
Increasingly, patients turn to social media for answers. Other people’s experiences can be useful, but TikTok videos, Facebook groups, commercial weight-loss advertising, and comments from strangers cannot substitute for sound patient education. People need to know what they can reasonably manage themselves, what should be discussed with their clinician, and what requires prompt medical attention.
My own experience eventually led me to create Body Compass. I did not create it because I believe GLP-1 medications are unsafe or because I want to persuade people not to take them. I created it because, despite my clinical background, I was struck by how much of the day-to-day experience of treatment sat outside the prescription. I kept thinking about the person without that background trying to make the same decisions alone.
As GLP-1 prescribing expands, patient education has to grow with it. People need realistic guidance about nutrition and hydration, maintaining strength, bowel health, side effects, changing appetite, plateaus, and what may happen when treatment is reduced, changed, or stopped. Some will need a dietitian, psychological support, or specialist medical care. Others may need good information, sensible expectations, and a clear route back to their clinician when something changes. We should not confuse access to a medication with a complete model of care.
GLP-1 medications have changed what is possible in obesity and metabolic treatment. The next task is less dramatic but just as important: making sure people know how to live safely and realistically with the treatment they have been prescribed.
A prescription can begin treatment. It cannot be the only plan.
Patience C. Ennis is a registered nurse, author, Results Coach, glucagon-like peptide-1 (GLP-1) user, and the founder of Body Compass, an education and navigation platform for people living with, considering, or moving beyond GLP-1 treatment. A graduate of King’s College London, she draws on more than three decades of clinical experience across emergency, community, palliative, and aged care, bringing together clinical knowledge, lived experience, and patient education to address the questions that often sit beyond the prescription.
Through Body Compass, she develops evidence-informed resources, books, practical tools, news updates, and non-clinical coaching support designed to help people understand changing appetite, side effects, strength, food noise, treatment adaptation, maintenance, and stopping. Her work is grounded in clarity, dignity, and honest interpretation of evidence, without hype, shame, or false certainty. Her aim is not to tell people what to decide, but to help them understand the terrain, ask better questions, and navigate metabolic health with greater confidence in everyday life and care.
She is the author of When GLP-1 Feels Different: Plateau, Food Noise, Adaptation and the Fear of “Resistance” (2026), available on Amazon and through Body Compass. Her other titles include Living Well on GLP-1 Medication: A Practical Guide to Everyday Life Beyond the Prescription, The Body Compass 30-Day Navigation Diary: A Reflective Daily Companion for GLP-1 Treatment, and The 30-Day GLP-1 Navigation Companion: Observation, Reflection, Preparation, Navigation.
She shares updates on LinkedIn, Facebook, the Body Compass Facebook page, Instagram, X, TikTok, and YouTube.
